Effect of Premeal Protein-bar on Glycemic Control in Patients With Type 2 Diabetes

NCT ID: NCT03727854

Last Updated: 2020-04-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-27

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effect of premeal protein-enriched bar in long-term glycemic control in patients with type 2 diabetes mellitus. Glucose levels in subjects who intake premeal protein-enriched bar with dietary modification will be compared to those in subjects who only do the dietary modification.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Forty subjects with type 2 diabetes will be recruited. Every subject will be randomized in two groups, which are premeal protein bar with dietary modification group and dietary modification only group. The study will be conducted for 12 weeks for each participants. All participants will receive diabetes diet education. Intervention group will consume protein-enriched bar before each meals (at least twice a day) and control group will follow diabetes diet education without other additional supplements. Primary outcome is change of HbA1c from baseline for 12 weeks, and secondary outcomes are changes of fasting blood glucose level, body weight, waist circumference, blood lipid level, HOMA-IR and HOMA-beta from baseline for 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Premeal protein group

Premeal protein enriched bar with dietary modification

Group Type EXPERIMENTAL

Premeal protein enriched bar

Intervention Type DIETARY_SUPPLEMENT

Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).

Dietary modification

Intervention Type BEHAVIORAL

Subjects in this group will follow diabetes diet education.

Dietary modofication only group

Dietary modification only

Group Type OTHER

Dietary modification

Intervention Type BEHAVIORAL

Subjects in this group will follow diabetes diet education.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Premeal protein enriched bar

Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).

Intervention Type DIETARY_SUPPLEMENT

Dietary modification

Subjects in this group will follow diabetes diet education.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI 18.5\~35 kg/m2
* Type 2 diabetes patients
* Fasting blood glucose ≥ 126 mg/dl or
* HbA1c ≥ 6.5% or
* Subjects who were previously diagnosed with type 2 diabetes and who have been treated with lifestyle modification only, oral anti-diabetic drugs or basal insulin.

Exclusion Criteria

* HbA1c \< 6.5% or \> 10%
* Subjects using insulin other than basal insulin
* Subjects who have newly started or have changed anti diabetic drugs within 3 months
* Subjects who are allergic to grains, nuts, legumes and milk
* Previous history of gastrointestinal surgery (except for hemorrhoid surgery, appendectomy surgery and hernia surgery)
* Subjects with chronic unstable disease
* Subjects with cognitive impairments who are not able to follow the study protocol
* Females who are pregnant or doing breast feeding
* Subjects with Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels of higher than 3 times of upper normal ranges
* Subjects with hemoglobin level of less than 10.0 g/dL
* Subjects with alcohol addiction or drug abuse
Minimum Eligible Age

19 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seoul National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Young Min Cho

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Young Min Cho, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Seoul National University Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-1804-120-940

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pre-meal Protein Drink Improve Glycemic Regulation
NCT01987674 TERMINATED PHASE1/PHASE2
Effects of Barley on Glucose Control
NCT02367989 ACTIVE_NOT_RECRUITING NA